Of note, PDX tumor 3101 had a low level of CD3+ staining and high staining for CD40 (Figure 1) and did not exhibit mutations in BRAF or NRAS, but there were mutations in NF1, FGFR, and CDKN2A, (see Table 2 for mutation profile for all PDX tumors studied). This evidence concerns the gene BRAF and neoplasm.